DDInter825 DDInter336
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Glimepiride {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Celecoxib
Glimepiride {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Celecoxib
Glimepiride {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) resembles {v} (Compound) Celecoxib
Glimepiride {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Celecoxib
Glimepiride {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Celecoxib
Glimepiride {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Celecoxib
Glimepiride {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Celecoxib
Glimepiride {u} (Compound) resembles {v} (Compound) Glyburide
Glyburide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Celecoxib
Glimepiride {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is associated with {v} (Gene) ZMIZ1
ZMIZ1 {u} (Gene) is downregulated by {v} (Compound) Celecoxib
Glimepiride {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) regulates {v} (Gene) ST3GAL5
ST3GAL5 {u} (Gene) is upregulated by {v} (Compound) Celecoxib
Glimepiride (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Celecoxib (Compound)
Glimepiride (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Celecoxib (Compound)
Glimepiride (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Celecoxib (Compound)
Glimepiride (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Celecoxib (Compound)
Glimepiride (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) binds ALB (Gene) and ALB (Gene) is bound by Celecoxib (Compound)
Glimepiride (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Celecoxib (Compound)
Glimepiride (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Celecoxib (Compound)
Glimepiride (Compound) resembles Glyburide (Compound) and Glyburide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Celecoxib (Compound)
Glimepiride (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is associated with ZMIZ1 (Gene) and ZMIZ1 (Gene) is downregulated by Celecoxib (Compound)
Glimepiride (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) regulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is upregulated by Celecoxib (Compound)